Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of sitagliptin 100 mg tablets vs Januvia 100 mg in healthy Thai participants under fasting
TCTR20251124001Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20251124001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251124001.